CSPC Pharma gets China clinical trial approval for cancer drug

CSPC Pharmaceutical Group announced that its SYS6036 Injection has obtained clinical trial approval from China's National Medical Products Administration.

The humanized monoclonal antibody is intended for cancer immunotherapy, targeting melanoma, non-small cell lung cancer, esophageal cancer, and head and neck squamous cell carcinoma.

Developed as a biosimilar, the product demonstrated high similarity to its reference drug in quality, safety, and efficacy during pharmaceutical and non-clinical studies.